Document is current
Any future updates will be listed below
-
Authors
Merker, Vanessa L. https://orcid.org/0000-0002-4542-5227
Knight, Pamela
Radtke, Heather B.
Yohay, Kaleb
Ullrich, Nicole J.
Plotkin, Scott R.
Jordan, Justin T. https://orcid.org/0000-0001-6198-817X
-
Funding
Funding for this research was provided by:
Children's Tumor Foundation
Office of Academic Affiliations, Department of Veterans Affairs (Advanced Fellowship Program in Health Services Research)
- License Information
-
More Information
Article History
Received: 14 October 2021
Accepted: 30 January 2022
First Online: 10 February 2022
Declarations
:
: The study protocol was reviewed by the Mass General Brigham Institutional Review Board and was deemed to meet criteria for exemption. Participation in the survey was voluntary and anonymous. Participants read a short fact sheet about the study and indicated their consent to participate by completing the survey.
: Not Applicable.
: The authors report no conflicts of interest pertinent to this manuscript. Financial disclosures for authors include the following: Dr. Merker reports consulting income from the Neurofibromatosis Network. Ms. Knight and Ms. Radtke are employees of the Children’s Tumor Foundation. Dr. Yohay reports consulting income from AstraZeneca and receives royalties from Wolters Kluwer. Dr. Ullrich reports patents held with University of Alabama Research Foundation; royalties from UpToDate; honoraria for speaking with AstraZeneca, and research support from the Children’s Tumor Foundation, Department of Defense and National Institutes of Health. Dr. Plotkin is co-founder of NFlection Therapeutics, Inc. and of NF2 Therapeutics, Inc and a consultant for AstraZeneca and for SonalaSense. Dr. Jordan receives royalties from Elsevier and reports consulting income from Navio Theragnostics, Health2047, and from CereXis.
